{"gene":"HTR6","run_date":"2026-06-10T01:55:22","timeline":{"discoveries":[{"year":1993,"finding":"The rat 5-HT6 receptor, when transiently expressed in transfected COS-7 cells, is positively coupled to cyclic AMP (cAMP) production, establishing it as a Gs-coupled GPCR.","method":"Transient transfection of COS-7 cells followed by cAMP accumulation assay","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct functional reconstitution in heterologous cells, replicated in multiple subsequent studies across independent labs","pmids":["8389146"],"is_preprint":false},{"year":1994,"finding":"5-HT6 receptors are positively coupled to adenylyl cyclase in striatal neurons in culture, confirming native receptor coupling to cAMP in brain neurons.","method":"Primary striatal neuron culture with cAMP level measurement and radioligand binding ([125I]-LSD)","journal":"Neuroreport","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro functional assay in native neurons, consistent with recombinant expression data","pmids":["7696602"],"is_preprint":false},{"year":1994,"finding":"5-HT6 receptors in pig caudate membranes stimulate adenylyl cyclase activity; methiothepin and clozapine act as surmountable antagonists, establishing the native tissue pharmacological coupling profile.","method":"Adenylyl cyclase assay in pig brain caudate membranes with pharmacological characterization","journal":"Naunyn-Schmiedeberg's archives of pharmacology","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — rigorous in vitro assay in native tissue, single lab, single method","pmids":["7845473"],"is_preprint":false},{"year":1996,"finding":"The human 5-HT6 receptor is positively coupled to adenylyl cyclase and has high affinity for typical and atypical antipsychotics including clozapine; the gene contains two introns in the third cytoplasmic loop and third extracellular loop.","method":"Recombinant expression, cAMP accumulation assay, radioligand binding, genomic cloning","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct functional characterization of recombinant human receptor with multiple orthogonal methods, replicated by other labs","pmids":["8522988"],"is_preprint":false},{"year":1997,"finding":"5-HT6 receptor-like immunoreactivity is localized to dendritic processes in the striatum and dentate gyrus of the hippocampus, indicating the receptor is trafficked to dendrites rather than axons.","method":"Immunohistochemistry (light and electron microscopy) using polyclonal anti-5-HT6 receptor antibodies in rat brain","journal":"Brain research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct subcellular localization by EM immunohistochemistry with antibody validated by ELISA, two brain regions examined","pmids":["9037500"],"is_preprint":false},{"year":1997,"finding":"Stably expressed rat 5-HT6 receptor in HEK293 cells stimulates cAMP accumulation; rank order of agonist potency established; several compounds (LSD, lisuride, 2-methyl-5-HT, tryptamine, 5-benzyloxytryptamine) act as partial agonists relative to 5-HT.","method":"Stable transfection of HEK293 cells, radioligand binding ([3H]-LSD, [3H]-5-HT), cAMP accumulation assay","journal":"Neuropharmacology","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted in stably expressing cells with binding and functional assays, multiple agonists/antagonists characterized","pmids":["9225298"],"is_preprint":false},{"year":1998,"finding":"5-HT6 receptor is expressed in rat brain from embryonic day 12 onward and is positively coupled to adenylyl cyclase in stably transfected CHO cells; antipsychotic and antidepressant drugs block 5-HT-stimulated cAMP production.","method":"Stable transfection of CHO cells, [3H]-5-HT binding, adenylyl cyclase assay, RT-PCR for developmental expression","journal":"Naunyn-Schmiedeberg's archives of pharmacology","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — functional reconstitution in CHO cells with pharmacological characterization, single lab","pmids":["9606024"],"is_preprint":false},{"year":1998,"finding":"Antisense oligonucleotide knockdown of 5-HT6 receptors in rat brain implicates the receptor in control of acetylcholine neurotransmission; 5-HT6 receptor antagonism (Ro 04-6790) in 6-OHDA lesioned rats inhibits scopolamine- and atropine-induced rotational behavior, supporting cholinergic modulation.","method":"Antisense oligonucleotide (icv infusion), pharmacological antagonism with Ro 04-6790, behavioral assessment in 6-OHDA lesion model","journal":"British journal of pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two orthogonal approaches (antisense knockdown and pharmacological antagonism) converging on cholinergic mechanism","pmids":["9884085"],"is_preprint":false},{"year":1999,"finding":"5-HT6 receptor-like immunoreactivity is associated with neuronal cilia in some limbic brain areas; antisense knockdown reduces 5-HT6 immunostaining in nucleus accumbens and produces anxiogenic behavior.","method":"Immunocytochemistry (light and electron microscopy), icv antisense oligonucleotide infusion, behavioral tests (social interaction, elevated plus maze)","journal":"Neuropsychopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct subcellular localization to cilia by EM plus functional knockdown with behavioral readout, single lab","pmids":["10432491"],"is_preprint":false},{"year":1999,"finding":"Antisense oligonucleotide knockdown of 5-ht6 reduced cortical [3H]-LSD binding sites and caused a behavioral syndrome of yawning, stretching, and chewing, indicating the receptor is under tonic control of endogenous 5-HT.","method":"Phosphorothioate antisense oligonucleotide treatment (icv), radioligand binding ([3H]-LSD), behavioral observation","journal":"Behavioural brain research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — antisense knockdown validated by binding reduction, specific behavioral phenotype, replicated in subsequent studies","pmids":["8788511"],"is_preprint":false},{"year":2001,"finding":"The mouse 5-HT6 receptor exhibits constitutive activity when transiently expressed in JEG-3 or COS-7 cells; point mutations in the BBXXB motif of the third cytoplasmic loop (K264I, K267A, A268R) reduce constitutive activity.","method":"Site-directed mutagenesis of the third cytoplasmic loop, cAMP-responsive reporter gene assay in JEG-3/COS-7 cells","journal":"Brain research. Molecular brain research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis combined with functional cAMP reporter assay, identifies specific residues controlling constitutive activity","pmids":["11406289"],"is_preprint":false},{"year":2003,"finding":"Mutation of Ser267 to Lys in the C-terminal region of the third intracellular loop (S267K) renders the human 5-HT6 receptor constitutively active; clozapine acts as an inverse agonist at this constitutively active mutant, reducing basal cAMP to vector control levels.","method":"PCR-based site-directed mutagenesis, expression in COS-7 cells, cAMP accumulation assay","journal":"Synapse (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis with functional cAMP assay, identifies C-terminal il3 as key domain for Gs coupling, inverse agonism of clozapine demonstrated","pmids":["12494404"],"is_preprint":false},{"year":2005,"finding":"A 3D pharmacophore model for 5-HT6R antagonists identifies key binding residues: Asp3.32 for ionic interaction with the protonated amine, Ser5.43 and Asn6.55 for hydrogen bonding, and a hydrophobic pocket between TM3/4/5 and Phe6.52.","method":"Computational pharmacophore modeling (Catalyst) using 45 structurally diverse antagonists with experimental binding validation","journal":"Journal of medicinal chemistry","confidence":"Low","confidence_rationale":"Tier 4 / Moderate — primarily computational with implicit experimental binding data, not directly validated by mutagenesis","pmids":["15974573"],"is_preprint":false},{"year":2006,"finding":"The C-terminal region of the 5-HT6 receptor interacts with the Fyn tyrosine kinase through Fyn's SH3 domain; activation of the 5-HT6 receptor activates ERK1/2 via a Fyn-dependent pathway.","method":"Yeast two-hybrid, GST pulldown assay, co-immunoprecipitation in two cell lines and rat brain, immunocytochemistry/immunohistochemistry, ERK1/2 phosphorylation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP validated in two cell lines and native brain tissue, GST pulldown identifies SH3 domain, functional ERK pathway activation demonstrated","pmids":["17189269"],"is_preprint":false},{"year":2006,"finding":"Increased viral-vector-mediated overexpression of 5-HT6 receptors in rat dorsomedial striatum impairs acquisition of instrumental (striatum-dependent) learning but not Morris water maze (hippocampus-dependent) learning; this deficit is reversed by 5-HT6 antagonist SB-258585.","method":"Viral-mediated gene transfer to rat striatum (dorsomedial vs. dorsocentral), instrumental learning task, Morris water maze, pharmacological rescue with SB-258585","journal":"Neuropsychopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — targeted gain-of-function in specific brain region with pharmacological rescue, region-specific behavioral specificity demonstrated","pmids":["17192775"],"is_preprint":false},{"year":2006,"finding":"E-6801 and E-6837 are partial agonists at the rat 5-HT6 receptor; Ro 04-6790 and SB-271046 act as inverse agonists/antagonists; a constitutively active S267K mutant receptor confirms inverse agonist properties of antagonists.","method":"Site-directed mutagenesis (S267K constitutively active mutant), cAMP assay with and without forskolin co-stimulation, pharmacological characterization in COS-7 cells","journal":"British journal of pharmacology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — constitutively active mutant combined with functional cAMP assay and multiple ligands, demonstrates inverse agonism of established antagonists","pmids":["16865095"],"is_preprint":false},{"year":2007,"finding":"Selective 5-HT6 receptor agonists WAY-181187 and WAY-208466 increase extracellular GABA in rat frontal cortex, dorsal hippocampus, striatum, and amygdala; the GABA elevation in the frontal cortex is blocked by 5-HT6 antagonist SB-271046 and by intracortical bicuculline, implicating 5-HT6 in the activation of local GABAergic interneurons.","method":"In vivo microdialysis in rat brain, pharmacological blockade with SB-271046 and bicuculline, in vitro hippocampal slice glutamate measurement","journal":"Neuropsychopharmacology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo microdialysis replicated across multiple brain regions, mechanism confirmed by receptor antagonist and GABAA receptor blockade, multiple orthogonal methods","pmids":["17625499"],"is_preprint":false},{"year":2007,"finding":"5-HT6 receptor agonism (EMDT) increases phosphorylation of Thr34-DARPP-32 and Ser845-GluR1 in brain slices and intact brain; these effects are independent of D1 receptor stimulation and can be blocked by the 5-HT6 antagonist SB271046.","method":"Western blot for phospho-protein levels in brain slices and in vivo, pharmacological blockade with SB271046, D1 receptor independence confirmed","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ex vivo and in vivo phosphorylation measured with receptor antagonist blockade, single lab","pmids":["17428998"],"is_preprint":false},{"year":2008,"finding":"5-HT6 receptor antagonists SB-271046 and SB-399885 increase NCAM polysialylation (PSA) of dentate granule cells in the hippocampus and entorhinal/perirhinal cortex in a dose-dependent manner, without increasing neurogenesis; they also enhance learning-associated polysialylation.","method":"Quantitative immunohistochemistry for NCAM PSA, BrdU incorporation for neurogenesis, chronic drug administration in rats","journal":"Neuropharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct neuroplasticity measurement with two 5-HT6 antagonists, neurogenesis ruled out as mechanism, single lab","pmids":["18455201"],"is_preprint":false},{"year":2010,"finding":"Site-directed mutagenesis identifies residues W6.48, F6.52, and N6.55 as critical for 5-HT6R antagonist binding; substitution of any of these with Ala fully abolishes the ability of compound 4 to block 5-HT-induced receptor activation.","method":"Site-directed mutagenesis, cAMP functional assay, homology modeling based on beta2-adrenoceptor structure","journal":"Journal of medicinal chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis with functional validation identifies specific binding pocket residues, combined with computational modeling","pmids":["20078106"],"is_preprint":false},{"year":2011,"finding":"5-HT6 receptor activation by agonist ST1936 reduces the frequency and amplitude of spontaneous excitatory postsynaptic currents (sEPSCs) in striatal medium spiny neurons (postsynaptic mechanism) and reduces only the frequency in cortical layer V pyramidal neurons (presynaptic or indirect mechanism); effects blocked by SB258585.","method":"Whole-cell patch-clamp electrophysiology in striatal and cortical brain slices, pharmacological blockade with SB258585, paired-pulse analysis, miniature EPSC recordings","journal":"Neuropharmacology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — rigorous electrophysiology with multiple complementary analyses distinguishing pre- vs. post-synaptic mechanisms, pharmacological specificity confirmed","pmids":["21619890"],"is_preprint":false},{"year":2014,"finding":"5-HT6 receptor constitutively interacts with cyclin-dependent kinase 5 (Cdk5); Cdk5 phosphorylates the receptor at Ser350, and this phosphorylation is required for 5-HT6R-elicited neurite growth in NG108-15 cells and primary neurons. Neurite growth is agonist-independent (constitutive), requires Cdc42 activity, and is prevented by 5-HT6 inverse agonist SB258585. Mutation of Ser350 to Ala abolishes the effect.","method":"Proteomic strategy to identify interactors, co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis (S350A), siRNA knockdown, neurite growth assay in NG108-15 cells and primary neurons","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods: proteomics, co-IP, mutagenesis, rescue experiments, primary neuron validation; mechanistically rigorous single study","pmids":["24880860"],"is_preprint":false},{"year":2016,"finding":"Neurofibromin (NF1 gene product) physically interacts with the 5-HT6 receptor and promotes its constitutive Gs/adenylyl cyclase signaling; disruption of the 5-HT6R–neurofibromin interaction via neurofibromin's Pleckstrin Homology (PH) domain, NF1 patient mutations, or neurofibromin silencing reduces constitutive cAMP signaling and CREB phosphorylation in prefrontal cortex.","method":"Co-immunoprecipitation, siRNA knockdown, PH domain expression/rescue, Nf1+/- mouse model, cAMP assay, CREB phosphorylation by western blot, in vivo 5-HT6 inverse agonist administration","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (co-IP, knockdown, rescue, patient mutations, in vivo mouse model) all convergently support the mechanism","pmids":["27791021"],"is_preprint":false},{"year":2016,"finding":"5-HT6 receptor antagonist SB271046 (idalopirdine class) potentiates donepezil-induced increases in hippocampal theta and gamma oscillations and extracellular acetylcholine levels in rats; idalopirdine alone has no effect on these parameters.","method":"In vivo electrophysiology (brainstem stimulation-evoked hippocampal oscillations in anesthetized rats), in vivo microdialysis (freely moving rats), pharmacokinetic interaction assessment","journal":"Neuropharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo electrophysiology and microdialysis with pharmacokinetic controls, single lab, demonstrates cholinergic potentiation mechanism","pmids":["27039041"],"is_preprint":false},{"year":2017,"finding":"5-HT6 receptor regulates the length and morphology of primary cilia in hippocampal neurons; overexpression elongates cilia, alters axon initial segment (AIS) morphology and AnkG/ARL13B localization, and reduces axonal length. Knockdown has opposite effects. These changes are linked to cognitive impairment in APP/PS1 AD model mice.","method":"Immunostaining, overexpression and siRNA knockdown in primary hippocampal neurons, APP/PS1 mouse model, behavioral testing (Morris water maze, Y-maze, fear conditioning)","journal":"Alzheimer's research & therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — bidirectional manipulation (OE and KD) with cellular readouts, in vivo AD model validation, single lab","pmids":["28931427"],"is_preprint":false},{"year":2019,"finding":"HTR6 (5-HT6 receptor)-mediated mTORC1 signaling is required for dietary restriction-induced memory enhancement; HTR6 inactivation diminishes DR-induced hippocampal neurological alterations (reduced dendritic complexity, increased spine density, enhanced LTP), linking the receptor to a nutrient-sensing pathway.","method":"HTR6 knockout/inactivation in Drosophila and mouse, dendritic morphology analysis, spine density measurement, LTP recording, mTORC1 signaling assay","journal":"PLoS biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function with multiple cellular readouts (morphology, LTP, signaling), links receptor to mTORC1/nutrient sensing pathway","pmids":["30883547"],"is_preprint":false},{"year":2014,"finding":"5-HT6 receptor blockade suppresses epileptic seizures and reduces mTOR activity in the pilocarpine rat model; HTR6 expression is upregulated in epileptic tissue, and SB-399885 (5-HT6 antagonist) suppresses both seizures and mTOR signaling, suggesting an HTR6/mTOR pathway in seizure regulation.","method":"Western blotting (HTR6 expression and mTOR activity), EEG recording, whole-cell patch clamp, pilocarpine rat model, pharmacological antagonism with SB-399885 ± rapamycin","journal":"Molecular neurobiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods (electrophysiology, EEG, western blot) with pharmacological and mTOR inhibitor controls, single lab","pmids":["25034463"],"is_preprint":false},{"year":2007,"finding":"Increased 5-HT6 receptor expression in rat nucleus accumbens (via viral-mediated gene transfer) blocks cocaine conditioned place preference (CPP) but has no effect on acute locomotor response to cocaine or development of cocaine-induced locomotor sensitization; pharmacological antagonism of 5-HT6R facilitates CPP acquisition.","method":"Viral-mediated gene transfer to NAc, conditioned place preference, locomotor sensitization, pharmacological antagonism with Ro4368554","journal":"Biological psychiatry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — region-specific gain-of-function with pharmacological complement, selective dissociation of reward vs. locomotor phenotypes","pmids":["17631868"],"is_preprint":false}],"current_model":"HTR6 (5-HT6R) is a Gs-coupled GPCR that constitutively and agonist-dependently activates adenylyl cyclase/cAMP signaling; it localizes predominantly to dendrites and primary cilia of striatal, limbic, and cortical neurons; its constitutive activity is promoted by physical interaction with neurofibromin (via its PH domain) and by Cdk5-mediated phosphorylation at Ser350, the latter driving agonist-independent neurite outgrowth and neuronal differentiation via Cdc42; agonist activation further recruits Fyn kinase (via the receptor C-terminus/Fyn SH3 domain) to stimulate ERK1/2, phosphorylates DARPP-32 and GluA1, and engages mTORC1 signaling; in the striatum, 5-HT6R activation inhibits corticostriatal glutamatergic transmission through both pre- and postsynaptic mechanisms, while in the frontal cortex it elevates GABAergic tone to modulate downstream glutamate and acetylcholine release, collectively underpinning its roles in cognitive consolidation, instrumental learning, reward processing, and seizure regulation."},"narrative":{"mechanistic_narrative":"HTR6 (5-HT6R) is a serotonin-activated, Gs-coupled GPCR that positively couples to adenylyl cyclase to drive cAMP production, a property established for the rat, human, and pig receptors in heterologous cells and native brain tissue [PMID:8389146, PMID:7696602, PMID:8522988]. The receptor displays robust constitutive (agonist-independent) activity that depends on the BBXXB motif and C-terminal residues of the third cytoplasmic loop, where mutations such as S267K lock the receptor in an active state and reveal that clinically used antagonists like clozapine behave as inverse agonists [PMID:11406289, PMID:12494404, PMID:16865095]. Antagonist binding is governed by a defined pocket including residues W6.48, F6.52, and N6.55 [PMID:20078106]. Constitutive Gs/cAMP signaling is amplified by physical interaction with neurofibromin through its PH domain, loss of which—via NF1 patient mutations or silencing—lowers basal cAMP and CREB phosphorylation in prefrontal cortex [PMID:27791021]. The receptor nucleates distinct effector pathways through direct protein partners: its C-terminus binds the SH3 domain of Fyn kinase to activate ERK1/2 [PMID:17189269], and it constitutively associates with Cdk5, which phosphorylates Ser350 to drive agonist-independent, Cdc42-dependent neurite outgrowth [PMID:24880860]. Downstream, agonist activation phosphorylates Thr34-DARPP-32 and Ser845-GluR1 independently of D1 receptors [PMID:17428998] and engages mTORC1 signaling implicated in memory and seizure regulation [PMID:30883547, PMID:25034463]. HTR6 localizes to dendrites and neuronal primary cilia, where it controls cilia length and axon initial segment morphology [PMID:9037500, PMID:10432491, PMID:28931427]. Functionally, the receptor modulates circuit activity by inhibiting corticostriatal glutamatergic transmission through pre- and postsynaptic mechanisms [PMID:21619890] and by elevating cortical GABAergic tone via local interneurons [PMID:17625499], collectively underpinning roles in instrumental learning, reward processing, and cholinergic neurotransmission [PMID:17192775, PMID:17631868, PMID:9884085].","teleology":[{"year":1993,"claim":"Established the fundamental signaling identity of the receptor by showing it positively drives cAMP, defining it as a Gs-coupled GPCR.","evidence":"Transient transfection of COS-7 cells with cAMP accumulation assay (rat receptor)","pmids":["8389146"],"confidence":"High","gaps":["Heterologous system only; native neuronal coupling not yet shown","No downstream effectors identified"]},{"year":1996,"claim":"Extended Gs/adenylyl cyclase coupling to the human receptor and revealed high affinity for typical and atypical antipsychotics, anchoring the receptor's pharmacological and clinical relevance.","evidence":"Recombinant human receptor expression, cAMP assay, radioligand binding, genomic cloning; corroborated in native striatal neurons and pig caudate membranes","pmids":["8522988","7696602","7845473"],"confidence":"High","gaps":["Mechanism of antipsychotic action at the receptor not resolved","No structural basis for ligand binding"]},{"year":1997,"claim":"Determined where the receptor acts in neurons by localizing it to dendritic processes, indicating postsynaptic/dendritic signaling rather than axonal.","evidence":"EM immunohistochemistry in rat striatum and dentate gyrus; agonist potency rank order established in stable HEK293 cells","pmids":["9037500","9225298"],"confidence":"Medium","gaps":["Trafficking determinants unknown","Cell-type specificity within regions not defined"]},{"year":1999,"claim":"Linked the receptor to tonic serotonergic control of behavior and identified a ciliary localization, while implicating it in cholinergic neurotransmission.","evidence":"icv antisense knockdown with radioligand binding and behavioral assays; EM immunocytochemistry to cilia; pharmacological antagonism in 6-OHDA lesion model","pmids":["8788511","10432491","9884085"],"confidence":"Medium","gaps":["Molecular basis of ciliary targeting unknown","Indirect cholinergic effects vs direct receptor action not separated"]},{"year":2003,"claim":"Mapped the structural determinants of constitutive activity to the third cytoplasmic loop and demonstrated inverse agonism, reframing antagonists as agents that suppress agonist-independent signaling.","evidence":"Site-directed mutagenesis (BBXXB motif, S267K constitutively active mutant) with cAMP reporter assays in COS-7/JEG-3 cells","pmids":["12494404","11406289","16865095"],"confidence":"High","gaps":["No full-length structure to explain constitutive activation","Physiological role of constitutive activity not yet established"]},{"year":2006,"claim":"Identified the first direct intracellular partner, showing the C-terminus binds Fyn via its SH3 domain to activate ERK1/2, revealing signaling beyond cAMP.","evidence":"Yeast two-hybrid, GST pulldown, reciprocal co-IP in two cell lines and rat brain, ERK1/2 phosphorylation assay","pmids":["17189269"],"confidence":"High","gaps":["Functional consequence of ERK activation in vivo unresolved","Relationship between Fyn/ERK and cAMP pathways not integrated"]},{"year":2006,"claim":"Demonstrated a behavioral role by showing striatal overexpression selectively impairs instrumental (striatum-dependent) learning, reversible by antagonist.","evidence":"Viral overexpression in rat dorsomedial striatum, instrumental and Morris water maze tasks, pharmacological rescue with SB-258585","pmids":["17192775"],"confidence":"Medium","gaps":["Circuit and molecular mediators of learning deficit not defined","Overexpression may not reflect endogenous levels"]},{"year":2007,"claim":"Connected the receptor to striatal/cortical signaling cascades and neurotransmitter circuits — phosphorylating DARPP-32 and GluR1, elevating cortical GABA, and modulating reward.","evidence":"Western blot phospho-protein analysis, in vivo microdialysis with antagonist and bicuculline blockade, viral overexpression in NAc with conditioned place preference","pmids":["17428998","17625499","17631868"],"confidence":"Medium","gaps":["Cell-type origin of GABA elevation only inferred","Link between phosphorylation events and behavior not directly tested"]},{"year":2011,"claim":"Resolved the synaptic-level action of the receptor, showing it inhibits glutamatergic transmission via distinct pre- and postsynaptic mechanisms in striatum and cortex.","evidence":"Whole-cell patch-clamp in striatal and cortical slices with paired-pulse and miniature EPSC analysis, SB258585 blockade","pmids":["21619890"],"confidence":"High","gaps":["Intracellular signaling underlying synaptic suppression not identified","In vivo relevance of slice findings not confirmed"]},{"year":2014,"claim":"Defined a constitutive, cAMP-independent signaling axis: Cdk5 binds and phosphorylates Ser350 to drive agonist-independent neurite growth via Cdc42, establishing the receptor as a regulator of neuronal morphogenesis.","evidence":"Proteomics, co-IP, in vitro kinase assay, S350A mutagenesis, siRNA, neurite assays in NG108-15 and primary neurons; parallel seizure/mTOR work in pilocarpine model","pmids":["24880860","25034463"],"confidence":"High","gaps":["How Ser350 phosphorylation engages Cdc42 mechanistically unclear","Interplay between constitutive morphogenic signaling and Gs/cAMP not integrated"]},{"year":2016,"claim":"Identified neurofibromin as a partner that sustains constitutive Gs signaling, linking the receptor's basal activity to NF1 biology and prefrontal CREB signaling.","evidence":"Co-IP, siRNA, PH domain rescue, NF1 patient mutations, Nf1+/- mouse, cAMP and CREB phosphorylation assays","pmids":["27791021"],"confidence":"High","gaps":["Structural basis of PH-domain/receptor interaction unknown","Clinical translation to NF1 cognitive phenotypes not established"]},{"year":2019,"claim":"Placed the receptor within a nutrient-sensing program, showing HTR6-mediated mTORC1 signaling is required for dietary-restriction-induced memory enhancement and hippocampal plasticity, complementing its control of cilia/AIS morphology.","evidence":"HTR6 loss-of-function in Drosophila and mouse, dendritic/spine morphology, LTP, mTORC1 assays; primary neuron cilia manipulation and APP/PS1 AD model","pmids":["30883547","28931427"],"confidence":"Medium","gaps":["Direct biochemical link between receptor and mTORC1 not fully defined","Whether cilia and mTORC1 phenotypes share a common effector unknown"]},{"year":null,"claim":"How the receptor's multiple, partly parallel outputs — constitutive Gs/cAMP, Cdk5/Ser350-Cdc42 morphogenesis, Fyn/ERK, and mTORC1 — are integrated and selected within a single neuron remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No experimentally determined full-length receptor structure in the corpus","Effector pathway crosstalk and bias not dissected","Human disease causality beyond NF1-associated signaling not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,3]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[22]}],"localization":[{"term_id":"GO:0005929","term_label":"cilium","supporting_discovery_ids":[8,24]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[4]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,3,13]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[16,20]}],"complexes":[],"partners":["FYN","CDK5","NF1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P50406","full_name":"5-hydroxytryptamine receptor 6","aliases":["Serotonin receptor 6"],"length_aa":440,"mass_kda":47.0,"function":"G-protein coupled receptor for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone and a mitogen (PubMed:35714614, PubMed:36989299, PubMed:37327704, PubMed:8522988). Also has a high affinity for tricyclic psychotropic drugs (By similarity). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors (PubMed:35714614). HTR6 is coupled to G(s) G alpha proteins and mediates activation of adenylate cyclase activity (PubMed:35714614, PubMed:37327704). Controls pyramidal neurons migration during corticogenesis, through the regulation of CDK5 activity (By similarity). Is an activator of mTOR signaling (PubMed:23027611)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P50406/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/HTR6","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/HTR6","total_profiled":1310},"omim":[{"mim_id":"601109","title":"5-@HYDROXYTRYPTAMINE RECEPTOR 6; HTR6","url":"https://www.omim.org/entry/601109"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in single","driving_tissues":[{"tissue":"brain","ntpm":7.0}],"url":"https://www.proteinatlas.org/search/HTR6"},"hgnc":{"alias_symbol":["5-HT6","5-HT6R"],"prev_symbol":[]},"alphafold":{"accession":"P50406","domains":[{"cath_id":"1.20.1070.10","chopping":"27-168_185-230_255-335","consensus_level":"medium","plddt":89.6884,"start":27,"end":335}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P50406","model_url":"https://alphafold.ebi.ac.uk/files/AF-P50406-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P50406-F1-predicted_aligned_error_v6.png","plddt_mean":72.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=HTR6","jax_strain_url":"https://www.jax.org/strain/search?query=HTR6"},"sequence":{"accession":"P50406","fasta_url":"https://rest.uniprot.org/uniprotkb/P50406.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P50406/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P50406"}},"corpus_meta":[{"pmid":"8389146","id":"PMC_8389146","title":"A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation.","date":"1993","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/8389146","citation_count":333,"is_preprint":false},{"pmid":"8522988","id":"PMC_8522988","title":"Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.","date":"1996","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8522988","citation_count":305,"is_preprint":false},{"pmid":"9037500","id":"PMC_9037500","title":"Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system.","date":"1997","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/9037500","citation_count":256,"is_preprint":false},{"pmid":"19086256","id":"PMC_19086256","title":"A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory.","date":"2008","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/19086256","citation_count":236,"is_preprint":false},{"pmid":"14965245","id":"PMC_14965245","title":"5-ht6 receptors.","date":"2004","source":"Current drug targets. CNS and neurological disorders","url":"https://pubmed.ncbi.nlm.nih.gov/14965245","citation_count":220,"is_preprint":false},{"pmid":"18625457","id":"PMC_18625457","title":"5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease.","date":"2008","source":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/18625457","citation_count":203,"is_preprint":false},{"pmid":"16005519","id":"PMC_16005519","title":"5-HT6 receptors: a novel target for cognitive enhancement.","date":"2005","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/16005519","citation_count":193,"is_preprint":false},{"pmid":"15223298","id":"PMC_15223298","title":"5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation--an effect sensitive to NMDA receptor antagonism.","date":"2004","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15223298","citation_count":167,"is_preprint":false},{"pmid":"11489457","id":"PMC_11489457","title":"A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze.","date":"2001","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11489457","citation_count":164,"is_preprint":false},{"pmid":"17625499","id":"PMC_17625499","title":"Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466.","date":"2007","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17625499","citation_count":159,"is_preprint":false},{"pmid":"10432491","id":"PMC_10432491","title":"Antibodies and antisense oligonucleotide for probing the distribution and putative functions of central 5-HT6 receptors.","date":"1999","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10432491","citation_count":159,"is_preprint":false},{"pmid":"18068807","id":"PMC_18068807","title":"Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders.","date":"2007","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/18068807","citation_count":144,"is_preprint":false},{"pmid":"25297016","id":"PMC_25297016","title":"Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.","date":"2014","source":"The Lancet. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25297016","citation_count":135,"is_preprint":false},{"pmid":"11702084","id":"PMC_11702084","title":"5-HT6 receptor antagonists enhance retention of a water maze task in the rat.","date":"2001","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11702084","citation_count":127,"is_preprint":false},{"pmid":"24850589","id":"PMC_24850589","title":"Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease.","date":"2014","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24850589","citation_count":125,"is_preprint":false},{"pmid":"17189269","id":"PMC_17189269","title":"The novel cellular mechanism of human 5-HT6 receptor through an interaction with Fyn.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17189269","citation_count":124,"is_preprint":false},{"pmid":"17428998","id":"PMC_17428998","title":"Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6 receptor stimulation.","date":"2007","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/17428998","citation_count":121,"is_preprint":false},{"pmid":"14571255","id":"PMC_14571255","title":"Differential involvement of 5-HT(1B/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer's disease.","date":"2004","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/14571255","citation_count":121,"is_preprint":false},{"pmid":"15846482","id":"PMC_15846482","title":"5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats.","date":"2005","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15846482","citation_count":101,"is_preprint":false},{"pmid":"24880860","id":"PMC_24880860","title":"Cdk5 induces constitutive activation of 5-HT6 receptors to promote neurite growth.","date":"2014","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/24880860","citation_count":100,"is_preprint":false},{"pmid":"16640790","id":"PMC_16640790","title":"Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients.","date":"2006","source":"BMC neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16640790","citation_count":98,"is_preprint":false},{"pmid":"20884998","id":"PMC_20884998","title":"Potential role of the 5-HT6 receptor in depression and anxiety: an overview of preclinical data.","date":"2010","source":"Pharmacological reports : PR","url":"https://pubmed.ncbi.nlm.nih.gov/20884998","citation_count":97,"is_preprint":false},{"pmid":"7696602","id":"PMC_7696602","title":"5-HT6 receptors positively coupled to adenylyl cyclase in striatal neurones in culture.","date":"1994","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/7696602","citation_count":95,"is_preprint":false},{"pmid":"10323584","id":"PMC_10323584","title":"Investigation of stretching behaviour induced by the selective 5-HT6 receptor antagonist, Ro 04-6790, in rats.","date":"1999","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10323584","citation_count":87,"is_preprint":false},{"pmid":"17922111","id":"PMC_17922111","title":"Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex.","date":"2007","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17922111","citation_count":86,"is_preprint":false},{"pmid":"20405281","id":"PMC_20405281","title":"E-6801, a 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat.","date":"2010","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20405281","citation_count":85,"is_preprint":false},{"pmid":"11406289","id":"PMC_11406289","title":"Cloning of the mouse 5-HT6 serotonin receptor and mutagenesis studies of the third cytoplasmic loop.","date":"2001","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/11406289","citation_count":82,"is_preprint":false},{"pmid":"23607787","id":"PMC_23607787","title":"5-HT6 receptors and Alzheimer's disease.","date":"2013","source":"Alzheimer's research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/23607787","citation_count":80,"is_preprint":false},{"pmid":"28931427","id":"PMC_28931427","title":"Serotonin 5-HT6 receptors affect cognition in a mouse model of Alzheimer's disease by regulating cilia function.","date":"2017","source":"Alzheimer's research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/28931427","citation_count":79,"is_preprint":false},{"pmid":"15964617","id":"PMC_15964617","title":"Oral administration of the 5-HT6 receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task.","date":"2005","source":"Pharmacology, biochemistry, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/15964617","citation_count":79,"is_preprint":false},{"pmid":"27791021","id":"PMC_27791021","title":"Physical interaction between neurofibromin and serotonin 5-HT6 receptor promotes receptor constitutive activity.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27791021","citation_count":74,"is_preprint":false},{"pmid":"9225298","id":"PMC_9225298","title":"Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells.","date":"1997","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/9225298","citation_count":74,"is_preprint":false},{"pmid":"9585121","id":"PMC_9585121","title":"Central distribution and function of 5-HT6 receptor subtype in the rat brain.","date":"1998","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/9585121","citation_count":73,"is_preprint":false},{"pmid":"29848076","id":"PMC_29848076","title":"The role of 5 HT6-receptor antagonists in Alzheimer's disease: an update.","date":"2018","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/29848076","citation_count":72,"is_preprint":false},{"pmid":"16783408","id":"PMC_16783408","title":"Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats.","date":"2006","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16783408","citation_count":71,"is_preprint":false},{"pmid":"10836139","id":"PMC_10836139","title":"5-ht6 receptors as emerging targets for drug discovery.","date":"2000","source":"Annual review of pharmacology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/10836139","citation_count":70,"is_preprint":false},{"pmid":"15974573","id":"PMC_15974573","title":"A three-dimensional pharmacophore model for 5-hydroxytryptamine6 (5-HT6) receptor antagonists.","date":"2005","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15974573","citation_count":70,"is_preprint":false},{"pmid":"18622410","id":"PMC_18622410","title":"Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat.","date":"2008","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18622410","citation_count":68,"is_preprint":false},{"pmid":"12112397","id":"PMC_12112397","title":"5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: autoradiographic studies with [125I]SB-258585.","date":"2002","source":"Synapse (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/12112397","citation_count":67,"is_preprint":false},{"pmid":"21414329","id":"PMC_21414329","title":"Influence of social isolation in the rat on serotonergic function and memory--relevance to models of schizophrenia and the role of 5-HT₆ receptors.","date":"2011","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21414329","citation_count":67,"is_preprint":false},{"pmid":"9884085","id":"PMC_9884085","title":"Involvement of 5-HT6 receptors in nigro-striatal function in rodents.","date":"1998","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/9884085","citation_count":67,"is_preprint":false},{"pmid":"11163544","id":"PMC_11163544","title":"Lack of association between the T-->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia.","date":"2001","source":"Schizophrenia research","url":"https://pubmed.ncbi.nlm.nih.gov/11163544","citation_count":65,"is_preprint":false},{"pmid":"26099069","id":"PMC_26099069","title":"Therapeutic Potential of 5-HT6 Receptor Agonists.","date":"2015","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26099069","citation_count":64,"is_preprint":false},{"pmid":"20217056","id":"PMC_20217056","title":"Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in rats.","date":"2010","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20217056","citation_count":64,"is_preprint":false},{"pmid":"17192775","id":"PMC_17192775","title":"Increased expression of 5-HT6 receptors in the rat dorsomedial striatum impairs instrumental learning.","date":"2006","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17192775","citation_count":64,"is_preprint":false},{"pmid":"20166958","id":"PMC_20166958","title":"5-HT6 receptor antagonists as potential therapeutics for cognitive impairment.","date":"2010","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20166958","citation_count":63,"is_preprint":false},{"pmid":"15771424","id":"PMC_15771424","title":"Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands.","date":"2005","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15771424","citation_count":63,"is_preprint":false},{"pmid":"27100049","id":"PMC_27100049","title":"Novel 1H-Pyrrolo[3,2-c]quinoline Based 5-HT6 Receptor Antagonists with Potential Application for the Treatment of Cognitive Disorders Associated with Alzheimer's Disease.","date":"2016","source":"ACS chemical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27100049","citation_count":62,"is_preprint":false},{"pmid":"26044973","id":"PMC_26044973","title":"5-HT6 Receptor Antagonists: Potential Efficacy for the Treatment of Cognitive Impairment in Schizophrenia.","date":"2015","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/26044973","citation_count":59,"is_preprint":false},{"pmid":"24805037","id":"PMC_24805037","title":"Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.","date":"2014","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24805037","citation_count":59,"is_preprint":false},{"pmid":"19549510","id":"PMC_19549510","title":"Dimebolin is a 5-HT6 antagonist with acute cognition enhancing activities.","date":"2009","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19549510","citation_count":58,"is_preprint":false},{"pmid":"21757018","id":"PMC_21757018","title":"Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats.","date":"2011","source":"Neurobiology of learning and memory","url":"https://pubmed.ncbi.nlm.nih.gov/21757018","citation_count":57,"is_preprint":false},{"pmid":"19589055","id":"PMC_19589055","title":"The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease.","date":"2009","source":"Expert review of neurotherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/19589055","citation_count":54,"is_preprint":false},{"pmid":"26424380","id":"PMC_26424380","title":"Distribution of serotonin receptor 5-HT6 mRNA in rat neuronal subpopulations: A double in situ hybridization study.","date":"2015","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/26424380","citation_count":53,"is_preprint":false},{"pmid":"10893499","id":"PMC_10893499","title":"Investigation of the human serotonin 6 [5-HT6] receptor gene in bipolar affective disorder and schizophrenia.","date":"2000","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10893499","citation_count":53,"is_preprint":false},{"pmid":"18729016","id":"PMC_18729016","title":"5-HT6 receptor antagonists: prospects for the treatment of cognitive disorders including dementia.","date":"2008","source":"Current opinion in drug discovery & development","url":"https://pubmed.ncbi.nlm.nih.gov/18729016","citation_count":52,"is_preprint":false},{"pmid":"12813582","id":"PMC_12813582","title":"Role of 5-HT6 receptors in memory formation.","date":"2001","source":"Drug news & perspectives","url":"https://pubmed.ncbi.nlm.nih.gov/12813582","citation_count":50,"is_preprint":false},{"pmid":"18691131","id":"PMC_18691131","title":"Serotonin 5-HT6 receptor antagonists for the treatment of Alzheimer's disease.","date":"2008","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18691131","citation_count":49,"is_preprint":false},{"pmid":"17207474","id":"PMC_17207474","title":"5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus.","date":"2007","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/17207474","citation_count":49,"is_preprint":false},{"pmid":"14741325","id":"PMC_14741325","title":"Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders.","date":"2004","source":"Schizophrenia research","url":"https://pubmed.ncbi.nlm.nih.gov/14741325","citation_count":48,"is_preprint":false},{"pmid":"18455201","id":"PMC_18455201","title":"The selective 5-HT6 receptor antagonists SB-271046 and SB-399885 potentiate NCAM PSA immunolabeling of dentate granule cells, but not neurogenesis, in the hippocampal formation of mature Wistar rats.","date":"2008","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18455201","citation_count":48,"is_preprint":false},{"pmid":"25590789","id":"PMC_25590789","title":"5-HT6 Receptor: A New Player Controlling the Development of Neural Circuits.","date":"2015","source":"ACS chemical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25590789","citation_count":47,"is_preprint":false},{"pmid":"21329783","id":"PMC_21329783","title":"5-HT6 receptor memory and amnesia: behavioral pharmacology--learning and memory processes.","date":"2011","source":"International review of neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/21329783","citation_count":47,"is_preprint":false},{"pmid":"23336058","id":"PMC_23336058","title":"Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation.","date":"2012","source":"ACS chemical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23336058","citation_count":47,"is_preprint":false},{"pmid":"7845473","id":"PMC_7845473","title":"5-Hydroxytryptamine receptors with a 5-HT6 receptor-like profile stimulating adenylyl cyclase activity in pig caudate membranes.","date":"1994","source":"Naunyn-Schmiedeberg's archives of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/7845473","citation_count":47,"is_preprint":false},{"pmid":"21499701","id":"PMC_21499701","title":"The 5-HT6 receptor agonist EMD 386088 produces antidepressant and anxiolytic effects in rats after intrahippocampal administration.","date":"2011","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21499701","citation_count":47,"is_preprint":false},{"pmid":"24698823","id":"PMC_24698823","title":"Memory formation and memory alterations: 5-HT6 and 5-HT7 receptors, novel alternative.","date":"2014","source":"Reviews in the neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/24698823","citation_count":46,"is_preprint":false},{"pmid":"16865095","id":"PMC_16865095","title":"Efficacy of selective 5-HT6 receptor ligands determined by monitoring 5-HT6 receptor-mediated cAMP signaling pathways.","date":"2006","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16865095","citation_count":46,"is_preprint":false},{"pmid":"16055331","id":"PMC_16055331","title":"2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists.","date":"2005","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/16055331","citation_count":46,"is_preprint":false},{"pmid":"8788511","id":"PMC_8788511","title":"Effects of altered 5-ht6 expression in the rat: functional studies using antisense oligonucleotides.","date":"1996","source":"Behavioural brain research","url":"https://pubmed.ncbi.nlm.nih.gov/8788511","citation_count":45,"is_preprint":false},{"pmid":"18197272","id":"PMC_18197272","title":"Prefrontal executive function and D1, D3, 5-HT2A and 5-HT6 receptor gene variations in healthy adults.","date":"2008","source":"Journal of psychiatry & neuroscience : JPN","url":"https://pubmed.ncbi.nlm.nih.gov/18197272","citation_count":45,"is_preprint":false},{"pmid":"22223878","id":"PMC_22223878","title":"Radiosynthesis and characterization of 11C-GSK215083 as a PET radioligand for the 5-HT6 receptor.","date":"2012","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22223878","citation_count":44,"is_preprint":false},{"pmid":"20078106","id":"PMC_20078106","title":"Benzimidazole derivatives as new serotonin 5-HT6 receptor antagonists. Molecular mechanisms of receptor inactivation.","date":"2010","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20078106","citation_count":44,"is_preprint":false},{"pmid":"10624811","id":"PMC_10624811","title":"Association analysis of the 5-HT6 receptor polymorphism C267T in Alzheimer's disease.","date":"1999","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/10624811","citation_count":44,"is_preprint":false},{"pmid":"17267053","id":"PMC_17267053","title":"Memory consolidation and amnesia modify 5-HT6 receptors expression in rat brain: an autoradiographic study.","date":"2007","source":"Behavioural brain research","url":"https://pubmed.ncbi.nlm.nih.gov/17267053","citation_count":42,"is_preprint":false},{"pmid":"10427606","id":"PMC_10427606","title":"Effects of clozapine and haloperidol on 5-HT6 receptor mRNA levels in rat brain.","date":"1999","source":"Schizophrenia research","url":"https://pubmed.ncbi.nlm.nih.gov/10427606","citation_count":40,"is_preprint":false},{"pmid":"17631868","id":"PMC_17631868","title":"Increased expression of 5-HT6 receptors in the nucleus accumbens blocks the rewarding but not psychomotor activating properties of cocaine.","date":"2007","source":"Biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/17631868","citation_count":40,"is_preprint":false},{"pmid":"26548316","id":"PMC_26548316","title":"Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease.","date":"2015","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/26548316","citation_count":39,"is_preprint":false},{"pmid":"19422883","id":"PMC_19422883","title":"Role of peripheral and spinal 5-HT6 receptors according to the rat formalin test.","date":"2009","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/19422883","citation_count":38,"is_preprint":false},{"pmid":"27326337","id":"PMC_27326337","title":"N1-Azinylsulfonyl-1H-indoles: 5-HT6 Receptor Antagonists with Procognitive and Antidepressant-Like Properties.","date":"2016","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/27326337","citation_count":38,"is_preprint":false},{"pmid":"15823158","id":"PMC_15823158","title":"Association between the 5-HT6 receptor C267T polymorphism and response to antidepressant treatment in major depressive disorder.","date":"2005","source":"Psychiatry and clinical neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/15823158","citation_count":38,"is_preprint":false},{"pmid":"22367167","id":"PMC_22367167","title":"5-HT6 receptor blockade differentially affects scopolamine-induced deficits of working memory, recognition memory and aversive learning in mice.","date":"2012","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22367167","citation_count":37,"is_preprint":false},{"pmid":"21619890","id":"PMC_21619890","title":"Activation of 5-HT6 receptors inhibits corticostriatal glutamatergic transmission.","date":"2011","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21619890","citation_count":36,"is_preprint":false},{"pmid":"26441657","id":"PMC_26441657","title":"5-HT6 receptor agonism facilitates emotional learning.","date":"2015","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26441657","citation_count":35,"is_preprint":false},{"pmid":"21866910","id":"PMC_21866910","title":"N'-(arylsulfonyl)pyrazoline-1-carboxamidines as novel, neutral 5-hydroxytryptamine 6 receptor (5-HT₆R) antagonists with unique structural features.","date":"2011","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21866910","citation_count":35,"is_preprint":false},{"pmid":"10206228","id":"PMC_10206228","title":"Association study of the 5-HT6 receptor gene in schizophrenia.","date":"1999","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10206228","citation_count":34,"is_preprint":false},{"pmid":"18201064","id":"PMC_18201064","title":"Binding of serotonin and N1-benzenesulfonyltryptamine-related analogs at human 5-HT6 serotonin receptors: receptor modeling studies.","date":"2008","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18201064","citation_count":34,"is_preprint":false},{"pmid":"10457531","id":"PMC_10457531","title":"Ionotropic glutamate receptor modulation of 5-HT6 and 5-HT7 mRNA expression in rat brain.","date":"1999","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10457531","citation_count":34,"is_preprint":false},{"pmid":"25034463","id":"PMC_25034463","title":"5-HT6 Receptor Recruitment of mTOR Modulates Seizure Activity in Epilepsy.","date":"2014","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/25034463","citation_count":33,"is_preprint":false},{"pmid":"27266998","id":"PMC_27266998","title":"Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease.","date":"2016","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27266998","citation_count":33,"is_preprint":false},{"pmid":"24501158","id":"PMC_24501158","title":"The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia.","date":"2014","source":"Reviews in the neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/24501158","citation_count":32,"is_preprint":false},{"pmid":"17920665","id":"PMC_17920665","title":"5-HT6 receptor antagonist reversal of emotional learning and prepulse inhibition deficits induced by apomorphine or scopolamine.","date":"2007","source":"Pharmacology, biochemistry, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/17920665","citation_count":32,"is_preprint":false},{"pmid":"20560595","id":"PMC_20560595","title":"(3-Phenylsulfonylcycloalkano[e and d]pyrazolo[1,5-a]pyrimidin-2-yl)amines: potent and selective antagonists of the serotonin 5-HT6 receptor.","date":"2010","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20560595","citation_count":32,"is_preprint":false},{"pmid":"30883547","id":"PMC_30883547","title":"Serotonin receptor HTR6-mediated mTORC1 signaling regulates dietary restriction-induced memory enhancement.","date":"2019","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/30883547","citation_count":31,"is_preprint":false},{"pmid":"18596685","id":"PMC_18596685","title":"Selective 5-HT6 receptor blockade improves spatial recognition memory and reverses age-related deficits in spatial recognition memory in the mouse.","date":"2008","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18596685","citation_count":31,"is_preprint":false},{"pmid":"29847336","id":"PMC_29847336","title":"SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization.","date":"2019","source":"Behavioural pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29847336","citation_count":31,"is_preprint":false},{"pmid":"12494404","id":"PMC_12494404","title":"Creation, expression, and characterization of a constitutively active mutant of the human serotonin 5-HT6 receptor.","date":"2003","source":"Synapse (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/12494404","citation_count":31,"is_preprint":false},{"pmid":"27039041","id":"PMC_27039041","title":"The 5-HT6 receptor antagonist idalopirdine potentiates the effects of acetylcholinesterase inhibition on neuronal network oscillations and extracellular acetylcholine levels in the rat dorsal hippocampus.","date":"2016","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27039041","citation_count":31,"is_preprint":false},{"pmid":"9928244","id":"PMC_9928244","title":"The putative 5-ht6 receptor: localization and function.","date":"1998","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/9928244","citation_count":30,"is_preprint":false},{"pmid":"9606024","id":"PMC_9606024","title":"Characterization of 5-ht6 receptor and expression of 5-ht6 mRNA in the rat brain during ontogenetic development.","date":"1998","source":"Naunyn-Schmiedeberg's archives of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/9606024","citation_count":30,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50468,"output_tokens":6718,"usd":0.126087,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15682,"output_tokens":4059,"usd":0.089942,"stage2_stop_reason":"end_turn"},"total_usd":0.216029,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"The rat 5-HT6 receptor, when transiently expressed in transfected COS-7 cells, is positively coupled to cyclic AMP (cAMP) production, establishing it as a Gs-coupled GPCR.\",\n      \"method\": \"Transient transfection of COS-7 cells followed by cAMP accumulation assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct functional reconstitution in heterologous cells, replicated in multiple subsequent studies across independent labs\",\n      \"pmids\": [\"8389146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"5-HT6 receptors are positively coupled to adenylyl cyclase in striatal neurons in culture, confirming native receptor coupling to cAMP in brain neurons.\",\n      \"method\": \"Primary striatal neuron culture with cAMP level measurement and radioligand binding ([125I]-LSD)\",\n      \"journal\": \"Neuroreport\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro functional assay in native neurons, consistent with recombinant expression data\",\n      \"pmids\": [\"7696602\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"5-HT6 receptors in pig caudate membranes stimulate adenylyl cyclase activity; methiothepin and clozapine act as surmountable antagonists, establishing the native tissue pharmacological coupling profile.\",\n      \"method\": \"Adenylyl cyclase assay in pig brain caudate membranes with pharmacological characterization\",\n      \"journal\": \"Naunyn-Schmiedeberg's archives of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — rigorous in vitro assay in native tissue, single lab, single method\",\n      \"pmids\": [\"7845473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The human 5-HT6 receptor is positively coupled to adenylyl cyclase and has high affinity for typical and atypical antipsychotics including clozapine; the gene contains two introns in the third cytoplasmic loop and third extracellular loop.\",\n      \"method\": \"Recombinant expression, cAMP accumulation assay, radioligand binding, genomic cloning\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct functional characterization of recombinant human receptor with multiple orthogonal methods, replicated by other labs\",\n      \"pmids\": [\"8522988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"5-HT6 receptor-like immunoreactivity is localized to dendritic processes in the striatum and dentate gyrus of the hippocampus, indicating the receptor is trafficked to dendrites rather than axons.\",\n      \"method\": \"Immunohistochemistry (light and electron microscopy) using polyclonal anti-5-HT6 receptor antibodies in rat brain\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct subcellular localization by EM immunohistochemistry with antibody validated by ELISA, two brain regions examined\",\n      \"pmids\": [\"9037500\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Stably expressed rat 5-HT6 receptor in HEK293 cells stimulates cAMP accumulation; rank order of agonist potency established; several compounds (LSD, lisuride, 2-methyl-5-HT, tryptamine, 5-benzyloxytryptamine) act as partial agonists relative to 5-HT.\",\n      \"method\": \"Stable transfection of HEK293 cells, radioligand binding ([3H]-LSD, [3H]-5-HT), cAMP accumulation assay\",\n      \"journal\": \"Neuropharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted in stably expressing cells with binding and functional assays, multiple agonists/antagonists characterized\",\n      \"pmids\": [\"9225298\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"5-HT6 receptor is expressed in rat brain from embryonic day 12 onward and is positively coupled to adenylyl cyclase in stably transfected CHO cells; antipsychotic and antidepressant drugs block 5-HT-stimulated cAMP production.\",\n      \"method\": \"Stable transfection of CHO cells, [3H]-5-HT binding, adenylyl cyclase assay, RT-PCR for developmental expression\",\n      \"journal\": \"Naunyn-Schmiedeberg's archives of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — functional reconstitution in CHO cells with pharmacological characterization, single lab\",\n      \"pmids\": [\"9606024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Antisense oligonucleotide knockdown of 5-HT6 receptors in rat brain implicates the receptor in control of acetylcholine neurotransmission; 5-HT6 receptor antagonism (Ro 04-6790) in 6-OHDA lesioned rats inhibits scopolamine- and atropine-induced rotational behavior, supporting cholinergic modulation.\",\n      \"method\": \"Antisense oligonucleotide (icv infusion), pharmacological antagonism with Ro 04-6790, behavioral assessment in 6-OHDA lesion model\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal approaches (antisense knockdown and pharmacological antagonism) converging on cholinergic mechanism\",\n      \"pmids\": [\"9884085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"5-HT6 receptor-like immunoreactivity is associated with neuronal cilia in some limbic brain areas; antisense knockdown reduces 5-HT6 immunostaining in nucleus accumbens and produces anxiogenic behavior.\",\n      \"method\": \"Immunocytochemistry (light and electron microscopy), icv antisense oligonucleotide infusion, behavioral tests (social interaction, elevated plus maze)\",\n      \"journal\": \"Neuropsychopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct subcellular localization to cilia by EM plus functional knockdown with behavioral readout, single lab\",\n      \"pmids\": [\"10432491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Antisense oligonucleotide knockdown of 5-ht6 reduced cortical [3H]-LSD binding sites and caused a behavioral syndrome of yawning, stretching, and chewing, indicating the receptor is under tonic control of endogenous 5-HT.\",\n      \"method\": \"Phosphorothioate antisense oligonucleotide treatment (icv), radioligand binding ([3H]-LSD), behavioral observation\",\n      \"journal\": \"Behavioural brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antisense knockdown validated by binding reduction, specific behavioral phenotype, replicated in subsequent studies\",\n      \"pmids\": [\"8788511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The mouse 5-HT6 receptor exhibits constitutive activity when transiently expressed in JEG-3 or COS-7 cells; point mutations in the BBXXB motif of the third cytoplasmic loop (K264I, K267A, A268R) reduce constitutive activity.\",\n      \"method\": \"Site-directed mutagenesis of the third cytoplasmic loop, cAMP-responsive reporter gene assay in JEG-3/COS-7 cells\",\n      \"journal\": \"Brain research. Molecular brain research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis combined with functional cAMP reporter assay, identifies specific residues controlling constitutive activity\",\n      \"pmids\": [\"11406289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Mutation of Ser267 to Lys in the C-terminal region of the third intracellular loop (S267K) renders the human 5-HT6 receptor constitutively active; clozapine acts as an inverse agonist at this constitutively active mutant, reducing basal cAMP to vector control levels.\",\n      \"method\": \"PCR-based site-directed mutagenesis, expression in COS-7 cells, cAMP accumulation assay\",\n      \"journal\": \"Synapse (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis with functional cAMP assay, identifies C-terminal il3 as key domain for Gs coupling, inverse agonism of clozapine demonstrated\",\n      \"pmids\": [\"12494404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"A 3D pharmacophore model for 5-HT6R antagonists identifies key binding residues: Asp3.32 for ionic interaction with the protonated amine, Ser5.43 and Asn6.55 for hydrogen bonding, and a hydrophobic pocket between TM3/4/5 and Phe6.52.\",\n      \"method\": \"Computational pharmacophore modeling (Catalyst) using 45 structurally diverse antagonists with experimental binding validation\",\n      \"journal\": \"Journal of medicinal chemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Moderate — primarily computational with implicit experimental binding data, not directly validated by mutagenesis\",\n      \"pmids\": [\"15974573\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The C-terminal region of the 5-HT6 receptor interacts with the Fyn tyrosine kinase through Fyn's SH3 domain; activation of the 5-HT6 receptor activates ERK1/2 via a Fyn-dependent pathway.\",\n      \"method\": \"Yeast two-hybrid, GST pulldown assay, co-immunoprecipitation in two cell lines and rat brain, immunocytochemistry/immunohistochemistry, ERK1/2 phosphorylation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP validated in two cell lines and native brain tissue, GST pulldown identifies SH3 domain, functional ERK pathway activation demonstrated\",\n      \"pmids\": [\"17189269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Increased viral-vector-mediated overexpression of 5-HT6 receptors in rat dorsomedial striatum impairs acquisition of instrumental (striatum-dependent) learning but not Morris water maze (hippocampus-dependent) learning; this deficit is reversed by 5-HT6 antagonist SB-258585.\",\n      \"method\": \"Viral-mediated gene transfer to rat striatum (dorsomedial vs. dorsocentral), instrumental learning task, Morris water maze, pharmacological rescue with SB-258585\",\n      \"journal\": \"Neuropsychopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — targeted gain-of-function in specific brain region with pharmacological rescue, region-specific behavioral specificity demonstrated\",\n      \"pmids\": [\"17192775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"E-6801 and E-6837 are partial agonists at the rat 5-HT6 receptor; Ro 04-6790 and SB-271046 act as inverse agonists/antagonists; a constitutively active S267K mutant receptor confirms inverse agonist properties of antagonists.\",\n      \"method\": \"Site-directed mutagenesis (S267K constitutively active mutant), cAMP assay with and without forskolin co-stimulation, pharmacological characterization in COS-7 cells\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — constitutively active mutant combined with functional cAMP assay and multiple ligands, demonstrates inverse agonism of established antagonists\",\n      \"pmids\": [\"16865095\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Selective 5-HT6 receptor agonists WAY-181187 and WAY-208466 increase extracellular GABA in rat frontal cortex, dorsal hippocampus, striatum, and amygdala; the GABA elevation in the frontal cortex is blocked by 5-HT6 antagonist SB-271046 and by intracortical bicuculline, implicating 5-HT6 in the activation of local GABAergic interneurons.\",\n      \"method\": \"In vivo microdialysis in rat brain, pharmacological blockade with SB-271046 and bicuculline, in vitro hippocampal slice glutamate measurement\",\n      \"journal\": \"Neuropsychopharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo microdialysis replicated across multiple brain regions, mechanism confirmed by receptor antagonist and GABAA receptor blockade, multiple orthogonal methods\",\n      \"pmids\": [\"17625499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"5-HT6 receptor agonism (EMDT) increases phosphorylation of Thr34-DARPP-32 and Ser845-GluR1 in brain slices and intact brain; these effects are independent of D1 receptor stimulation and can be blocked by the 5-HT6 antagonist SB271046.\",\n      \"method\": \"Western blot for phospho-protein levels in brain slices and in vivo, pharmacological blockade with SB271046, D1 receptor independence confirmed\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ex vivo and in vivo phosphorylation measured with receptor antagonist blockade, single lab\",\n      \"pmids\": [\"17428998\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"5-HT6 receptor antagonists SB-271046 and SB-399885 increase NCAM polysialylation (PSA) of dentate granule cells in the hippocampus and entorhinal/perirhinal cortex in a dose-dependent manner, without increasing neurogenesis; they also enhance learning-associated polysialylation.\",\n      \"method\": \"Quantitative immunohistochemistry for NCAM PSA, BrdU incorporation for neurogenesis, chronic drug administration in rats\",\n      \"journal\": \"Neuropharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct neuroplasticity measurement with two 5-HT6 antagonists, neurogenesis ruled out as mechanism, single lab\",\n      \"pmids\": [\"18455201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Site-directed mutagenesis identifies residues W6.48, F6.52, and N6.55 as critical for 5-HT6R antagonist binding; substitution of any of these with Ala fully abolishes the ability of compound 4 to block 5-HT-induced receptor activation.\",\n      \"method\": \"Site-directed mutagenesis, cAMP functional assay, homology modeling based on beta2-adrenoceptor structure\",\n      \"journal\": \"Journal of medicinal chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis with functional validation identifies specific binding pocket residues, combined with computational modeling\",\n      \"pmids\": [\"20078106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"5-HT6 receptor activation by agonist ST1936 reduces the frequency and amplitude of spontaneous excitatory postsynaptic currents (sEPSCs) in striatal medium spiny neurons (postsynaptic mechanism) and reduces only the frequency in cortical layer V pyramidal neurons (presynaptic or indirect mechanism); effects blocked by SB258585.\",\n      \"method\": \"Whole-cell patch-clamp electrophysiology in striatal and cortical brain slices, pharmacological blockade with SB258585, paired-pulse analysis, miniature EPSC recordings\",\n      \"journal\": \"Neuropharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — rigorous electrophysiology with multiple complementary analyses distinguishing pre- vs. post-synaptic mechanisms, pharmacological specificity confirmed\",\n      \"pmids\": [\"21619890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"5-HT6 receptor constitutively interacts with cyclin-dependent kinase 5 (Cdk5); Cdk5 phosphorylates the receptor at Ser350, and this phosphorylation is required for 5-HT6R-elicited neurite growth in NG108-15 cells and primary neurons. Neurite growth is agonist-independent (constitutive), requires Cdc42 activity, and is prevented by 5-HT6 inverse agonist SB258585. Mutation of Ser350 to Ala abolishes the effect.\",\n      \"method\": \"Proteomic strategy to identify interactors, co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis (S350A), siRNA knockdown, neurite growth assay in NG108-15 cells and primary neurons\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods: proteomics, co-IP, mutagenesis, rescue experiments, primary neuron validation; mechanistically rigorous single study\",\n      \"pmids\": [\"24880860\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Neurofibromin (NF1 gene product) physically interacts with the 5-HT6 receptor and promotes its constitutive Gs/adenylyl cyclase signaling; disruption of the 5-HT6R–neurofibromin interaction via neurofibromin's Pleckstrin Homology (PH) domain, NF1 patient mutations, or neurofibromin silencing reduces constitutive cAMP signaling and CREB phosphorylation in prefrontal cortex.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, PH domain expression/rescue, Nf1+/- mouse model, cAMP assay, CREB phosphorylation by western blot, in vivo 5-HT6 inverse agonist administration\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (co-IP, knockdown, rescue, patient mutations, in vivo mouse model) all convergently support the mechanism\",\n      \"pmids\": [\"27791021\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"5-HT6 receptor antagonist SB271046 (idalopirdine class) potentiates donepezil-induced increases in hippocampal theta and gamma oscillations and extracellular acetylcholine levels in rats; idalopirdine alone has no effect on these parameters.\",\n      \"method\": \"In vivo electrophysiology (brainstem stimulation-evoked hippocampal oscillations in anesthetized rats), in vivo microdialysis (freely moving rats), pharmacokinetic interaction assessment\",\n      \"journal\": \"Neuropharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo electrophysiology and microdialysis with pharmacokinetic controls, single lab, demonstrates cholinergic potentiation mechanism\",\n      \"pmids\": [\"27039041\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"5-HT6 receptor regulates the length and morphology of primary cilia in hippocampal neurons; overexpression elongates cilia, alters axon initial segment (AIS) morphology and AnkG/ARL13B localization, and reduces axonal length. Knockdown has opposite effects. These changes are linked to cognitive impairment in APP/PS1 AD model mice.\",\n      \"method\": \"Immunostaining, overexpression and siRNA knockdown in primary hippocampal neurons, APP/PS1 mouse model, behavioral testing (Morris water maze, Y-maze, fear conditioning)\",\n      \"journal\": \"Alzheimer's research & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — bidirectional manipulation (OE and KD) with cellular readouts, in vivo AD model validation, single lab\",\n      \"pmids\": [\"28931427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HTR6 (5-HT6 receptor)-mediated mTORC1 signaling is required for dietary restriction-induced memory enhancement; HTR6 inactivation diminishes DR-induced hippocampal neurological alterations (reduced dendritic complexity, increased spine density, enhanced LTP), linking the receptor to a nutrient-sensing pathway.\",\n      \"method\": \"HTR6 knockout/inactivation in Drosophila and mouse, dendritic morphology analysis, spine density measurement, LTP recording, mTORC1 signaling assay\",\n      \"journal\": \"PLoS biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function with multiple cellular readouts (morphology, LTP, signaling), links receptor to mTORC1/nutrient sensing pathway\",\n      \"pmids\": [\"30883547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"5-HT6 receptor blockade suppresses epileptic seizures and reduces mTOR activity in the pilocarpine rat model; HTR6 expression is upregulated in epileptic tissue, and SB-399885 (5-HT6 antagonist) suppresses both seizures and mTOR signaling, suggesting an HTR6/mTOR pathway in seizure regulation.\",\n      \"method\": \"Western blotting (HTR6 expression and mTOR activity), EEG recording, whole-cell patch clamp, pilocarpine rat model, pharmacological antagonism with SB-399885 ± rapamycin\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods (electrophysiology, EEG, western blot) with pharmacological and mTOR inhibitor controls, single lab\",\n      \"pmids\": [\"25034463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Increased 5-HT6 receptor expression in rat nucleus accumbens (via viral-mediated gene transfer) blocks cocaine conditioned place preference (CPP) but has no effect on acute locomotor response to cocaine or development of cocaine-induced locomotor sensitization; pharmacological antagonism of 5-HT6R facilitates CPP acquisition.\",\n      \"method\": \"Viral-mediated gene transfer to NAc, conditioned place preference, locomotor sensitization, pharmacological antagonism with Ro4368554\",\n      \"journal\": \"Biological psychiatry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — region-specific gain-of-function with pharmacological complement, selective dissociation of reward vs. locomotor phenotypes\",\n      \"pmids\": [\"17631868\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HTR6 (5-HT6R) is a Gs-coupled GPCR that constitutively and agonist-dependently activates adenylyl cyclase/cAMP signaling; it localizes predominantly to dendrites and primary cilia of striatal, limbic, and cortical neurons; its constitutive activity is promoted by physical interaction with neurofibromin (via its PH domain) and by Cdk5-mediated phosphorylation at Ser350, the latter driving agonist-independent neurite outgrowth and neuronal differentiation via Cdc42; agonist activation further recruits Fyn kinase (via the receptor C-terminus/Fyn SH3 domain) to stimulate ERK1/2, phosphorylates DARPP-32 and GluA1, and engages mTORC1 signaling; in the striatum, 5-HT6R activation inhibits corticostriatal glutamatergic transmission through both pre- and postsynaptic mechanisms, while in the frontal cortex it elevates GABAergic tone to modulate downstream glutamate and acetylcholine release, collectively underpinning its roles in cognitive consolidation, instrumental learning, reward processing, and seizure regulation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"HTR6 (5-HT6R) is a serotonin-activated, Gs-coupled GPCR that positively couples to adenylyl cyclase to drive cAMP production, a property established for the rat, human, and pig receptors in heterologous cells and native brain tissue [#0, #1, #3]. The receptor displays robust constitutive (agonist-independent) activity that depends on the BBXXB motif and C-terminal residues of the third cytoplasmic loop, where mutations such as S267K lock the receptor in an active state and reveal that clinically used antagonists like clozapine behave as inverse agonists [#10, #11, #15]. Antagonist binding is governed by a defined pocket including residues W6.48, F6.52, and N6.55 [#19]. Constitutive Gs/cAMP signaling is amplified by physical interaction with neurofibromin through its PH domain, loss of which—via NF1 patient mutations or silencing—lowers basal cAMP and CREB phosphorylation in prefrontal cortex [#22]. The receptor nucleates distinct effector pathways through direct protein partners: its C-terminus binds the SH3 domain of Fyn kinase to activate ERK1/2 [#13], and it constitutively associates with Cdk5, which phosphorylates Ser350 to drive agonist-independent, Cdc42-dependent neurite outgrowth [#21]. Downstream, agonist activation phosphorylates Thr34-DARPP-32 and Ser845-GluR1 independently of D1 receptors [#17] and engages mTORC1 signaling implicated in memory and seizure regulation [#25, #26]. HTR6 localizes to dendrites and neuronal primary cilia, where it controls cilia length and axon initial segment morphology [#4, #8, #24]. Functionally, the receptor modulates circuit activity by inhibiting corticostriatal glutamatergic transmission through pre- and postsynaptic mechanisms [#20] and by elevating cortical GABAergic tone via local interneurons [#16], collectively underpinning roles in instrumental learning, reward processing, and cholinergic neurotransmission [#14, #27, #7].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Established the fundamental signaling identity of the receptor by showing it positively drives cAMP, defining it as a Gs-coupled GPCR.\",\n      \"evidence\": \"Transient transfection of COS-7 cells with cAMP accumulation assay (rat receptor)\",\n      \"pmids\": [\"8389146\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Heterologous system only; native neuronal coupling not yet shown\", \"No downstream effectors identified\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Extended Gs/adenylyl cyclase coupling to the human receptor and revealed high affinity for typical and atypical antipsychotics, anchoring the receptor's pharmacological and clinical relevance.\",\n      \"evidence\": \"Recombinant human receptor expression, cAMP assay, radioligand binding, genomic cloning; corroborated in native striatal neurons and pig caudate membranes\",\n      \"pmids\": [\"8522988\", \"7696602\", \"7845473\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of antipsychotic action at the receptor not resolved\", \"No structural basis for ligand binding\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Determined where the receptor acts in neurons by localizing it to dendritic processes, indicating postsynaptic/dendritic signaling rather than axonal.\",\n      \"evidence\": \"EM immunohistochemistry in rat striatum and dentate gyrus; agonist potency rank order established in stable HEK293 cells\",\n      \"pmids\": [\"9037500\", \"9225298\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Trafficking determinants unknown\", \"Cell-type specificity within regions not defined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Linked the receptor to tonic serotonergic control of behavior and identified a ciliary localization, while implicating it in cholinergic neurotransmission.\",\n      \"evidence\": \"icv antisense knockdown with radioligand binding and behavioral assays; EM immunocytochemistry to cilia; pharmacological antagonism in 6-OHDA lesion model\",\n      \"pmids\": [\"8788511\", \"10432491\", \"9884085\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of ciliary targeting unknown\", \"Indirect cholinergic effects vs direct receptor action not separated\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Mapped the structural determinants of constitutive activity to the third cytoplasmic loop and demonstrated inverse agonism, reframing antagonists as agents that suppress agonist-independent signaling.\",\n      \"evidence\": \"Site-directed mutagenesis (BBXXB motif, S267K constitutively active mutant) with cAMP reporter assays in COS-7/JEG-3 cells\",\n      \"pmids\": [\"12494404\", \"11406289\", \"16865095\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No full-length structure to explain constitutive activation\", \"Physiological role of constitutive activity not yet established\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identified the first direct intracellular partner, showing the C-terminus binds Fyn via its SH3 domain to activate ERK1/2, revealing signaling beyond cAMP.\",\n      \"evidence\": \"Yeast two-hybrid, GST pulldown, reciprocal co-IP in two cell lines and rat brain, ERK1/2 phosphorylation assay\",\n      \"pmids\": [\"17189269\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of ERK activation in vivo unresolved\", \"Relationship between Fyn/ERK and cAMP pathways not integrated\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrated a behavioral role by showing striatal overexpression selectively impairs instrumental (striatum-dependent) learning, reversible by antagonist.\",\n      \"evidence\": \"Viral overexpression in rat dorsomedial striatum, instrumental and Morris water maze tasks, pharmacological rescue with SB-258585\",\n      \"pmids\": [\"17192775\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Circuit and molecular mediators of learning deficit not defined\", \"Overexpression may not reflect endogenous levels\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Connected the receptor to striatal/cortical signaling cascades and neurotransmitter circuits — phosphorylating DARPP-32 and GluR1, elevating cortical GABA, and modulating reward.\",\n      \"evidence\": \"Western blot phospho-protein analysis, in vivo microdialysis with antagonist and bicuculline blockade, viral overexpression in NAc with conditioned place preference\",\n      \"pmids\": [\"17428998\", \"17625499\", \"17631868\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell-type origin of GABA elevation only inferred\", \"Link between phosphorylation events and behavior not directly tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Resolved the synaptic-level action of the receptor, showing it inhibits glutamatergic transmission via distinct pre- and postsynaptic mechanisms in striatum and cortex.\",\n      \"evidence\": \"Whole-cell patch-clamp in striatal and cortical slices with paired-pulse and miniature EPSC analysis, SB258585 blockade\",\n      \"pmids\": [\"21619890\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intracellular signaling underlying synaptic suppression not identified\", \"In vivo relevance of slice findings not confirmed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined a constitutive, cAMP-independent signaling axis: Cdk5 binds and phosphorylates Ser350 to drive agonist-independent neurite growth via Cdc42, establishing the receptor as a regulator of neuronal morphogenesis.\",\n      \"evidence\": \"Proteomics, co-IP, in vitro kinase assay, S350A mutagenesis, siRNA, neurite assays in NG108-15 and primary neurons; parallel seizure/mTOR work in pilocarpine model\",\n      \"pmids\": [\"24880860\", \"25034463\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Ser350 phosphorylation engages Cdc42 mechanistically unclear\", \"Interplay between constitutive morphogenic signaling and Gs/cAMP not integrated\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified neurofibromin as a partner that sustains constitutive Gs signaling, linking the receptor's basal activity to NF1 biology and prefrontal CREB signaling.\",\n      \"evidence\": \"Co-IP, siRNA, PH domain rescue, NF1 patient mutations, Nf1+/- mouse, cAMP and CREB phosphorylation assays\",\n      \"pmids\": [\"27791021\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of PH-domain/receptor interaction unknown\", \"Clinical translation to NF1 cognitive phenotypes not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Placed the receptor within a nutrient-sensing program, showing HTR6-mediated mTORC1 signaling is required for dietary-restriction-induced memory enhancement and hippocampal plasticity, complementing its control of cilia/AIS morphology.\",\n      \"evidence\": \"HTR6 loss-of-function in Drosophila and mouse, dendritic/spine morphology, LTP, mTORC1 assays; primary neuron cilia manipulation and APP/PS1 AD model\",\n      \"pmids\": [\"30883547\", \"28931427\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biochemical link between receptor and mTORC1 not fully defined\", \"Whether cilia and mTORC1 phenotypes share a common effector unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the receptor's multiple, partly parallel outputs — constitutive Gs/cAMP, Cdk5/Ser350-Cdc42 morphogenesis, Fyn/ERK, and mTORC1 — are integrated and selected within a single neuron remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No experimentally determined full-length receptor structure in the corpus\", \"Effector pathway crosstalk and bias not dissected\", \"Human disease causality beyond NF1-associated signaling not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 3]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005929\", \"supporting_discovery_ids\": [8, 24]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 3, 13]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [16, 20]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"FYN\", \"CDK5\", \"NF1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}